Effective August 2, 2022, mdxhealth has acquired the Oncotype DX Genomic Prostate Score (GPS) test from Exact Sciences. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the press release.
Questions? Email: gps@mdxhealth.com

Only the Oncotype DX Breast Recurrence Score® Test Predicts Chemotherapy Benefit. MammaPrint® Does Not.1-5*

 

The Breast Recurrence Score® test predicts both chemotherapy benefit and lack of benefit1,2

Only the Breast Recurrence Score test predicts who may, or may not, benefit from chemotherapy, regardless of clinical risk status.1,2,4,5,7

 

NSABP B-202

Graph NSABP B20

TAILORx1

Graph TAILORx

MammaPrint did not show prediction of chemotherapy benefit in the MINDACT study6

MammaPrint may lead to overtreatment or undertreatment based on its risk classification result.

 

Patients randomized to chemotherapy (intent-to-treat)

Identified as MammaPrint Low Risk and clinical High Risk

Patients showed a trend toward chemotherapy benefit (31% risk reduction)
5-year DMFS 95.7 vs 93.2 (CT vs no CT), P = ns
Adjusted HR: 0.69 (95% CI, 0.39, 1.21)

Identified as MammaPrint High Risk and clinical Low Risk

Patients did not receive a benefit chemotherapy
5-year DMFS 96.0 vs 95.1 (CT vs no CT)
Adjusted HR: 1.09 (95% CI, 0.54, 2.19)

MammaPrint categorizes a substantially larger number of patients as high risk compared with the Oncotype DX Breast Recurrence Score test8

Graph pooled risk group

 

MammaPrint has poor agreement (74%) with the Breast Recurrence Score test in patient risk stratification8

Graph Breast Recurrence Score vs MammaPrint

Low Risk (-1 in 4 patients (n=70/247) potentially overtreated8

High Risk (-1 in 4 patients (n=6/50) potentially overtreated8

Only the Breast Recurrence Score test predicts who may, or may not, benefit from chemotherapy, regardless of clinical risk status, to safely spare patients from overtreatment or undertreatment.1,2,4,5,7

See why the Breast Recurrence Score test rises above

 

 

*MammaPrint has not shown proof of prediction of chemotherapy benefit.
MammaPrint is a registered trademark of Agendia, Inc. MammaPrint is a registered trademark of Agendia BV. Please refer to this manufacturer directly for more information.

Icon doctor

Use our online physician portal

Order tests, access results, receive updates, and more in one place.
Sign up now